Article
Oncology
Lauren Averett Byers, Dmitry Bentsion, Steven Gans, Konstantin Penkov, ChoonHee Son, Anne Sibille, Taofeek K. Owonikoko, Harry J. M. Groen, Carl M. Gay, Junya Fujimoto, Patricia de Groot, Martin Dunbar, Kingston Kang, Lei He, Vasudha Sehgal, Jaimee Glasgow, Bruce Allen Bach, Peter M. Ellis
Summary: The study found that veliparib combined with platinum chemotherapy and maintenance therapy improved progression-free survival in first-line treatment of ED-SCLC, but did not show a corresponding benefit in overall survival. Patients may experience common hematologic toxicities during treatment. Further research is needed to determine the role of biomarkers in this setting.
CLINICAL CANCER RESEARCH
(2021)
Article
Biochemistry & Molecular Biology
Jyh-Der Leu, Shih-Ting Lin, Chiung-Tong Chen, C-Allen Chang, Yi-Jang Lee
Summary: BPR0C261 demonstrates dose-dependent cytotoxicity on A549 and H1299 cells, inducing maximum G2/M phase arrest and apoptosis in both cell lines. The combination of low concentration of BPR0C261 and X-rays shows a synergistic radiosensitizing effect on NSCLC cells.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Cell Biology
Qing Wang, Liqiong Zhang, Youchuan Xiao, Asghar Ghaemnezhad
Summary: Phytopharmaceuticals can enhance the effectiveness of conventional chemotherapy and reduce drug resistance in cisplatin-based chemotherapy. This study investigated the effects of diosgenin (DG) combined with cisplatin on apoptosis and its mechanisms in non-small cell lung cancer cells, and found that DG significantly increased the cytotoxic effects of cisplatin and induced apoptosis in tumor cells.
CELL BIOLOGY INTERNATIONAL
(2022)
Article
Medicine, General & Internal
Ibrahim Azar, Omid Yazdanpanah, Hyejeong Jang, Adam Austin, Seongho Kim, Jie Chi, Samer Alkassis, Biplab K. Saha, Amit Chopra, Kristoffer Neu, Syed Mehdi, Hirva Mamdani
Summary: There is no significant difference in survival outcomes between cisplatin and carboplatin for the treatment of both limited-stage and extensive-stage small cell lung cancer (SCLC). The favorable toxicity profile of carboplatin and comparable overall survival support its use in clinical practice for both types of SCLC and allow for combination with novel treatment strategies in clinical trials.
Article
Oncology
Ting He, Yinglei Gao, Yanfen Fang, Yangming Zhang, Shuwei Zhang, Fajun Nan, Jian Ding, Yi Chen
Summary: This study found that GCJ-490A effectively inhibited the proliferation of NSCLC cells and induced apoptosis both in vitro and in vivo. Furthermore, GCJ-490A increased histone acetylation at the IKK?? promoter by inhibiting HDAC1 and HDAC6, resulting in the downregulation of c-Met. This downregulation was essential for the synergistic anti-tumor activity of GCJ-490A and gefitinib. These findings provide a potential strategy for NSCLC treatment by using HDAC inhibitors in combination with EGFR inhibitors.
CANCER BIOLOGY & MEDICINE
(2022)
Article
Oncology
Yuanyuan Zheng, Longhao Wang, Xiaoyu Niu, Yongjun Guo, Jiuzhou Zhao, Lifeng Li, Jie Zhao
Summary: This study found that the pan-DUB inhibitor EOAI can inhibit tumor growth and enhance the anti-tumor effect of cisplatin in NSCLC tissues. It induces cell cycle arrest, autophagy, and apoptosis by modulating the transcriptional activity of p53 and causing DNA damage. This finding provides ideas for potential targeted therapy in NSCLC.
Article
Biochemistry & Molecular Biology
Shikha Mahajan, Anurima Majumder, Paul A. Stewart, Yian Ann Chen, Emma Adhikari, Bin Fang, Yan Yang, Harshani Lawrence, Fumi Kinose, John M. Koomen, Eric B. Haura
Summary: In this study, we combined activity-based protein profiling and mass spectrometry to identify 67 DUBs in non-small cell lung cancer tissues. We found 12 DUBs that had an impact on lung cancer cell viability and further investigated the biological significance of one of these DUBs, COPS6. This study provides valuable insights into DUB signaling biology and identifies potential drug targets for treating specific subtypes of lung cancer.
ACS CHEMICAL BIOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Yingming Sun, Xiaoge Sun, Chengcheng You, Shijing Ma, Yuan Luo, Shan Peng, Fang Tang, Xiaoli Tian, Feng Wang, Zhengrong Huang, Hongnv Yu, Yu Xiao, Xiaoyong Wang, Junhong Zhang, Yan Gong, Conghua Xie
Summary: MUC3A is highly expressed in non-small cell lung cancer (NSCLC) and associated with poor prognosis, advanced staging, and low differentiation. Knockdown of MUC3A suppresses tumor growth and DNA damage repair pathways, suggesting it may be a potential oncogene.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
(2021)
Article
Biochemistry & Molecular Biology
Dehua Lu, Lailiang Qu, Cheng Wang, Heng Luo, Shang Li, Fucheng Yin, Xingchen Liu, Xinye Chen, Zhongwen Luo, Ningjie Cui, Wan Peng, Limei Ji, Lingyi Kong, Xiaobing Wang
Summary: Combining HDAC inhibitors with DNA damage agents has shown promise in treating solid tumors. We designed a series of harmine-based inhibitors, with compound 27 showing potential in binding to DNA and causing DNA damage. Compound 27 induced cell apoptosis through the p53 signaling pathway and exhibited significant anti-proliferation effects against HCT-116 cells.
BIOORGANIC CHEMISTRY
(2022)
Article
Biochemistry & Molecular Biology
Hongfang Zhang, Ke Zhang, Liqing Qiu, Jing Yue, Hong Jiang, Qinghua Deng, Rongjing Zhou, Zihao Yin, Shenglin Ma, Yuehai Ke
Summary: Radiotherapy is important for treating non-small cell lung cancer (NSCLC) patients, but tumor radioresistance limits its efficacy. Our study shows that cancer-associated fibroblasts (CAFs), a component of the tumor microenvironment, inhibit DNA damage and promote repair of NSCLC cells after irradiation, leading to cell cycle arrest in the radioresistant S phase. CAFs upregulate c-Myc and activate the Wnt/β-catenin pathway, resulting in increased glycolysis. Attenuating glycolysis reverses the effect of CAFs on DNA damage response. In vivo, CAFs promote radioresistance by promoting glycolysis through the β-catenin pathway. These findings suggest new strategies for reversing radioresistance in NSCLC cells.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
(2023)
Article
Chemistry, Multidisciplinary
Xing-mei Liang, Qiong Qin, Bo-ning Liu, Xiao-qing Li, Li-li Zeng, Jing Wang, Ling-ping Kong, Dian-sheng Zhong, Lin-lin Sun
Summary: The study reveals that DNA damage repair capacity is compromised in osimertinib-resistant cells, and inhibiting DNA-PK can increase sensitivity to osimertinib. Combination of osimertinib with DNA-PK inhibitors synergistically suppresses proliferation of resistant cells.
ACTA PHARMACOLOGICA SINICA
(2021)
Article
Biochemistry & Molecular Biology
Emily C. Sutton, Victoria J. DeRose
Summary: Recent reports suggest that oxaliplatin causes early nucleolar disruption via inhibition of rRNA synthesis, while cisplatin kills cells primarily via DNA damage without significant effects on nucleolar organization.
JOURNAL OF BIOLOGICAL CHEMISTRY
(2021)
Article
Cell Biology
Kaili Long, Lili Gu, Lulu Li, Ziyu Zhang, Enjie Li, Yilan Zhang, Lingfeng He, Feiyan Pan, Zhigang Guo, Zhigang Hu
Summary: APE1 plays a critical role in NSCLC and its inhibitor NO.0449-0145 induces DNA damage and cell death, overcoming resistance to traditional chemotherapy in NSCLC cells. These findings highlight the therapeutic potential of targeting APE1 in NSCLC and developing small-molecule drugs for the treatment of other cancers.
CELL DEATH & DISEASE
(2021)
Article
Cell Biology
Ji-Hyun Kim, Eunji Im, Jihyun Lee, Hyo-Jung Lee, Deok Yong Sim, Ji Eon Park, Chi-Hoon Ahn, Hyeon Hee Kwon, Bum Sang Shim, Bonglee Kim, Sung-Hoon Kim
Summary: The apoptotic mechanism of PGG in cisplatin-resistant lung cancer cells was investigated. PGG was found to induce apoptosis through upregulation of DNA damage proteins, such as γ-H(2)AX, pCHK2, and p53.
Article
Pharmacology & Pharmacy
Yan Li, Ke Li, Weihao Zhao, Haodong Wang, Xiaodong Xue, Xianghui Chen, Wantao Li, Peihao Xu, Kexin Wang, Pengfei Liu, Xuefei Tian, Rongguo Fu
Summary: This study found that valproic acid (VPA) prevents cisplatin-induced renal injury through regulating glutathione peroxidase 4 (GPX4) and inhibiting ferroptosis. This suggests that inhibiting ferroptosis through VPA is a viable treatment for cisplatin-induced acute kidney injury.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Hematology
Yinuo Wang, Xiaosu Zhao, Xiaoyang Ye, Hongxue Luo, Tongfeng Zhao, Yarui Diao, Hongyu Zhang, Meng Lv, Wei Zhang, Xiaojun Huang, Jun Wan
ANNALS OF HEMATOLOGY
(2015)
Article
Chemistry, Multidisciplinary
Xinghua Gao, Yeung Yeung Chau, Jiao Xie, Jun Wan, Yanxiao Ren, Jianhua Qin, Weijia Wen
Article
Geriatrics & Gerontology
Xiaoyang Ye, Hongxue Luo, Yan Chen, Qi Wu, Yi Xiong, Jinyong Zhu, Yarui Diao, Zhenguo Wu, Jianting Miao, Jun Wan
FRONTIERS IN AGING NEUROSCIENCE
(2015)
Article
Materials Science, Biomaterials
Cong Wang, Xinghua Gao, Yibo Gao, Wenbin Cao, Jingxuan Tian, Xiaoxiao Wu, Ziran Ye, Xiping Zeng, Bingpu Zhou, Jinbo Wu, Zhengyu Fang, Jun Wan, Jianhua Qin, Weijia Wen
JOURNAL OF MATERIALS CHEMISTRY B
(2015)
Article
Oncology
Xiao-su Zhao, Yi-nuo Wang, Meng-Lv, Yuan-Kong, Hong-xue Luo, Xiao-yang Ye, Qi Wu, Tong-feng Zhao, Yue-huan Hu, Hong-yu Zhang, Ming-rui-Huo, Jun-Wan, Xiao-jun Huang
Article
Geriatrics & Gerontology
Chunying Fan, Qi Wu, Xiaoyang Ye, Hongxue Luo, Dongdong Yan, Yi Xiong, Haili Zhu, Yarui Diao, Wei Zhang, Jun Wan
FRONTIERS IN AGING NEUROSCIENCE
(2016)
Article
Biochemical Research Methods
Hua Wang, Wei Zhang, Jun Wan, Weiwei Liu, Bo Yu, Qinghui Jin, Ming Guan
ANALYTICAL BIOCHEMISTRY
(2014)
Article
Immunology
Kepeng Wang, Min Kyoung Kim, Giuseppe Di Caro, Jerry Wong, Shabnam Shalapour, Jun Wan, Wei Zhang, Zhenyu Zhong, Elsa Sanchez-Lopez, Li-Wha Wu, Koji Taniguchi, Ying Feng, Eric Fearon, Sergei I. Grivennikov, Michael Karin
Article
Biochemistry & Molecular Biology
Jixiang Zhu, Yi Xiong, Chenguang Zeng, Na Qiang, Daping Quan, Jun Wan
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
(2012)
Article
Biochemistry & Molecular Biology
Yarui Diao, Xing Guo, Lei Jiang, Gang Wang, Chao Zhang, Jun Wan, Yan Jin, Zhenguo Wu
JOURNAL OF BIOLOGICAL CHEMISTRY
(2014)
Article
Biochemical Research Methods
Zhihong Liu, Yang Xiang, Zhun Wei, Bo Yu, Yong Shao, Jie Zhang, Hong Yang, Manmei Li, Ming Guan, Jun Wan, Wei Zhang
JOURNAL OF VIROLOGICAL METHODS
(2013)
Article
Multidisciplinary Sciences
Jufeng Zhang, Ying Wang, Pingping Zhen, Xia Luo, Chao Zhang, Lin Zhou, Yanxin Lu, Yang Yang, Wei Zhang, Jun Wan
Article
Multidisciplinary Sciences
Jufeng Zhang, Yanxin Lu, Xupeng Yue, Huiming Li, Xia Luo, Ying Wang, Kepeng Wang, Jun Wan
Article
Multidisciplinary Sciences
Hongxue Luo, Qi Wu, Xiaoyang Ye, Yi Xiong, Jinyong Zhu, Junyu Xu, Yarui Diao, Duo Zhang, Maosheng Wang, Jinhua Qiu, Jianting Miao, Wei Zhang, Jun Wan
Review
Medicine, Research & Experimental
Weizhuo Lu, Zhiwu Chen, Jiyue Wen
Summary: Ischemic stroke is a common and serious disease, and neuroinflammation plays a crucial role in its progression. Microglia, astrocytes, and infiltrating immune cells are involved in the complicated neuroinflammation cascade, releasing different molecules that affect inflammation. Flavonoids, plant-specific compounds, have shown protective effects against cerebral ischemia injury by modulating the inflammatory responses.
BIOMEDICINE & PHARMACOTHERAPY
(2024)